CD274 and gastroesophageal junction adenocarcinoma: This survival benefit was most pronounced in patients with ESCC and PD-L1 CPS ≥10 (median overall survival 13.9 versus 8.8 months), whereas there was no significant benefit observed in patients with CPS <10.37 These results led to approval of pembrolizumab in the first-line treatment of locally advanced or metastatic ESCC, adenocarcinoma of the esophagus and GEJ adenocarcinoma with high PD-L1 expression (CPS ≥10).